ClinicalTrials.gg

Program

anbenitamab repodatecan

Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Stomach Neoplasms · Ovarian Neoplasms, led by 2 companies.

Furthest: phase 3, since Sep 22, 20238 company-led studies, 7 open or runningLicense: Alphamab → CSPC (JMT-Bio), Sep 2024Next primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncology43 open or runningphase 3since Sep 22, 2023Aug 4, 2022Dec 30, 2026phase 3 · NCT06751485
CSPC Pharmaceutical Group44 open or runningphase 3since Jan 6, 2025Jan 6, 2025May 29, 2027phase 2 · NCT07545044
  • Named in CSPC Pharmaceutical Group’s own pipeline as anbenitamab repodatecan (JSKN003), phase 3, as of Aug 20, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2022First study: phase 1 study in Advanced Solid TumorsNew to Alphamab OncologyAlphamab Oncology · NCT05494918 · 62 enrolled · Australia
  2. Jan 10, 2023Phase 2 study in Advanced Solid TumorAlphamab Oncology · NCT05744427 · 725 enrolled · China
  3. Sep 22, 2023Phase 3 study in Breast NeoplasmsAlphamab Oncology · NCT06079983 · 400 planned · China
  4. Sep 30, 2024CSPC (JMT-Bio) licensed it from AlphamabLicenseMainland China, in cancer · announced · Alphamab Oncology (release)
  5. Dec 25, 2024Phase 3 study in Ovarian NeoplasmsAlphamab Oncology · NCT06751485 · 430 planned
  6. Jan 6, 2025CSPC Pharmaceutical Group’s first study: phase 3 study in Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer ParticipantsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06846437 · 228 planned · China
  7. May 12, 2025Phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771 · 153 planned
  8. Jan 26, 2026Phase 3 study in HER2-positive Colorectal CancerCSPC Pharmaceutical Group · NCT07384377 · 123 planned
  9. Apr 15, 2026Phase 2 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT07545044 · 60 planned

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Ovarian NeoplasmsAlphamab Oncology · NCT06751485
  2. May 29, 2027Primary completion: phase 2 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT07545044
  3. Nov 30, 2027Primary completion: phase 3 study in HER2-positive Colorectal CancerCSPC Pharmaceutical Group · NCT07384377
  4. Jun 30, 2028Primary completion: phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771

TargetBeta

“An antibody-drug conjugate (ADC) composed of the bispecific monoclonal antibody anbenitamab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2)…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of the bispecific monoclonal antibody anbenitamab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), s”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07545044Breast Neoplasms2Not yet recruitingCSPC Pharmaceutical GroupMay 29, 202760
NCT07384377HER2-positive Colorectal Cancer3Not yet recruitingCSPC Pharmaceutical GroupNov 30, 2027123
NCT06998771HER2-positive Gastric Cancer2Not yet recruitingCSPC Pharmaceutical GroupJun 30, 2028153
NCT06846437Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants · China3RecruitingCSPC Pharmaceutical GroupOct 13, 2026228
NCT06751485Ovarian Neoplasms3Not yet recruitingAlphamab OncologyDec 30, 2026430
NCT06079983Breast Neoplasms · China3RecruitingAlphamab OncologyApr 1, 2026400
NCT05744427Advanced Solid Tumor · China2Active, not recruitingAlphamab OncologyJul 30, 2026725
NCT05494918Advanced Solid Tumors · Australia1CompletedAlphamab OncologyApr 15, 202562

How it is read

Names in the registry

  • “JSKN003”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.